A $15M upfront payment is due at signing; FDA acceptance is expected in August 2026, with a U.S. launch targeted for Q1 2027 if approved.Read More
PolyPid’s D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3
By Stock Titan
MGSN.net
